Treatment strategy for metastatic luminal HER2-negative breast cancer with germline BRCA1/2 mutations: clinical experience with olaparib

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Among breast cancer cases, approximately 10% are associated with mutations in the BRCA1/2 genes, and about 50% of these cases present with a luminal HER2-negative phenotype. The standard first-line therapy for this subtype is sequential lines of hormone therapy, including combinations with various targeted drugs (CZK4/6 inhibitors, PI3K inhibitors, mTOR). PARP inhibitors are also a possible option for the treatment of metastatic BRCA-associated HER2-negative breast cancer.

We present a clinical case of successful use of olaparib as a third-line therapy for metastatic luminal HER2-negative breast cancer. Through this case, we discuss the role of various treatment strategies in managing metastatic BRCA-associated luminal HER2-negative breast cancer.

Full Text

Restricted Access

About the authors

Mona A. Frolova

Blokhin National Medical Research Center of Oncology

Author for correspondence.
Email: drfrolova@yandex.ru
ORCID iD: 0000-0002-8149-0085
SPIN-code: 2809-7737

MD, Dr. Sci. (Medicine)

Russian Federation, 24 Kashirskoye highway, Moscow 115478

Marina B. Stenina

Blokhin National Medical Research Center of Oncology

Email: mstenina@mail.ru
ORCID iD: 0000-0001-5304-9682
SPIN-code: 4722-1219

MD, Dr. Sci. (Medicine)

Russian Federation, 24 Kashirskoye highway, Moscow 115478

References

  1. Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology. 2020;31(12):1623–1649. doi: 10.1016/j.annonc.2020.09.010
  2. Tyulyandin SA, Artamonova EV, Zhigulev AN, et al. Breast cancer. Malignant tumours. 2023;13(3s2-1):157–200. doi: 10.18027/2224-5057-2023-13-3s2-1-157-200
  3. Gennari A, André F, Barrios CH, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Annals of Oncology. 2021;32(12):1475–1495. doi: 10.1016/j.annonc.2021.09.019
  4. Mavaddat N, Barrowdale D, Andrulis IL, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology, Biomarkers & Prevention. 2012;21(1):134–147. doi: 10.1158/1055-9965.EPI-11-0775
  5. Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clinical Cancer Research. 2007;13(5):1383–1388. doi: 10.1158/1055-9965.EPI-11-0775
  6. Lord CJ, Ashworth A. Targeted therapy for cancer using PARP inhibitors. Current Opinion in Pharmacology. 2008;8(4):363–369. doi: 10.1016/j.coph.2008.06.016
  7. Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. The New England Journal of Medicine. 2017;377(6):523–533. doi: 10.1056/NEJMoa1706450
  8. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. The New England Journal of Medicine. 2018;23(379):753–763. doi: 10.1056/NEJMoa1802905
  9. Collins JM, Nordstrom BL, McLaurin KK, et al. A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status. Oncology and Therapy. 2021;9:575–589. doi: 10.1007/s40487-021-00162-4

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Timeline.

Download (147KB)

Copyright (c) 2024 Eco-Vector



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 86496 от 11.12.2023 г
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ЭЛ № ФС 77 - 80673 от 23.03.2021 г
.